CU20150067A7 - 3-CARBOXI-N-ETIL-N, N-DIMETILPROPAN-1-AMINIO AND PHARMACEUTICALLY ACCEPTABLE SALTS TO TREAT ATEROCLEROSIS - Google Patents
3-CARBOXI-N-ETIL-N, N-DIMETILPROPAN-1-AMINIO AND PHARMACEUTICALLY ACCEPTABLE SALTS TO TREAT ATEROCLEROSISInfo
- Publication number
- CU20150067A7 CU20150067A7 CUP2015000067A CU20150067A CU20150067A7 CU 20150067 A7 CU20150067 A7 CU 20150067A7 CU P2015000067 A CUP2015000067 A CU P2015000067A CU 20150067 A CU20150067 A CU 20150067A CU 20150067 A7 CU20150067 A7 CU 20150067A7
- Authority
- CU
- Cuba
- Prior art keywords
- pharmaceutically acceptable
- acceptable salts
- dimetilpropan
- ateroclerosis
- carboxi
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- ISMYCKWHOZKHNJ-UHFFFAOYSA-O 3-carboxypropyl-ethyl-dimethylazanium Chemical compound CC[N+](C)(C)CCCC(O)=O ISMYCKWHOZKHNJ-UHFFFAOYSA-O 0.000 abstract 1
- DQSCWIHGBKJVRY-UHFFFAOYSA-N 3-carboxypropyl-ethyl-dimethylazanium;dihydrogen phosphate Chemical compound OP(O)([O-])=O.CC[N+](C)(C)CCCC(O)=O DQSCWIHGBKJVRY-UHFFFAOYSA-N 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 230000003143 atherosclerotic effect Effects 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-M fumarate(1-) Chemical compound OC(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-M 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se describe un compuesto y se presenta su fórmula 3-carboxi-N-etil-N,N-dimetilpropan-1-aminio y sus sales farmacéuticamente aceptables: fumarato de hidrógeno de 3-carboxi-N-etil-N, N-dimetilpropan-1-aminio y fosfato de dihidrógeno 3-carboxi-N-etil-N,N-dimetilpropan-1-aminio. El compuesto y las sales de la presente invención es efectivo para el tratamiento de la aterosclerosis por disminución del área y volumen total de las lesiones ateroesclerótica, con fórmula: ESPACIO PARA FÓRMULAA compound is described and its formula 3-carboxy-N-ethyl-N, N-dimethylpropan-1-aminium and its pharmaceutically acceptable salts are presented: 3-carboxy-N-ethyl-N hydrogen fumarate, N-dimethylpropan- 1-Aminium and 3-carboxy-N-ethyl-N, N-dimethylpropan-1-aminium dihydrogen phosphate. The compound and salts of the present invention are effective for the treatment of atherosclerosis by decreasing the area and total volume of atherosclerotic lesions, with formula: SPACE FOR FORMULA
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12198627 | 2012-12-20 | ||
| PCT/EP2013/077291 WO2014096133A1 (en) | 2012-12-20 | 2013-12-19 | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the treatment of atherosclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20150067A7 true CU20150067A7 (en) | 2016-01-29 |
Family
ID=47458734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CUP2015000067A CU20150067A7 (en) | 2012-12-20 | 2015-06-19 | 3-CARBOXI-N-ETIL-N, N-DIMETILPROPAN-1-AMINIO AND PHARMACEUTICALLY ACCEPTABLE SALTS TO TREAT ATEROCLEROSIS |
Country Status (11)
| Country | Link |
|---|---|
| CN (1) | CN104869988B (en) |
| AR (1) | AR094084A1 (en) |
| BR (1) | BR112015014161B1 (en) |
| CA (1) | CA2895574C (en) |
| CU (1) | CU20150067A7 (en) |
| JO (1) | JO3117B1 (en) |
| MX (1) | MX362762B (en) |
| PE (1) | PE20151587A1 (en) |
| TN (1) | TN2015000236A1 (en) |
| WO (1) | WO2014096133A1 (en) |
| ZA (1) | ZA201505093B (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA021588B1 (en) * | 2009-06-25 | 2015-07-30 | Тетра Сиа | Betain salts of acetylsalicylic acid |
| WO2010149654A1 (en) * | 2009-06-25 | 2010-12-29 | Grindeks, A Joint Stock Company | Pharmaceutical composition of gamma-butyrobetaine or a pharmaceutically acceptable salt and meldonium or a pharmaceutically acceptable salt |
| LV14345B (en) * | 2009-10-22 | 2011-07-20 | Grindeks, A/S | 4- [Ethyl (dimethyl) ammonium] butano ā and t ā uses š an cardiovascular ā ro slim ī bu ā rst ē š |
| BR112013027065B1 (en) * | 2011-04-27 | 2019-12-03 | Grindeks Jsc | Process for the preparation of 3-carboxy-n-ethyl-n, n-dimethylpropan-1-ammonium salts, compounds and their uses |
-
2013
- 2013-12-11 JO JOP/2013/0362A patent/JO3117B1/en active
- 2013-12-18 AR ARP130104820A patent/AR094084A1/en unknown
- 2013-12-19 CA CA2895574A patent/CA2895574C/en active Active
- 2013-12-19 MX MX2015008138A patent/MX362762B/en active IP Right Grant
- 2013-12-19 WO PCT/EP2013/077291 patent/WO2014096133A1/en not_active Ceased
- 2013-12-19 PE PE2015000876A patent/PE20151587A1/en not_active Application Discontinuation
- 2013-12-19 BR BR112015014161-7A patent/BR112015014161B1/en active IP Right Grant
- 2013-12-19 CN CN201380066810.0A patent/CN104869988B/en active Active
-
2015
- 2015-06-01 TN TNP2015000236A patent/TN2015000236A1/en unknown
- 2015-06-19 CU CUP2015000067A patent/CU20150067A7/en unknown
- 2015-07-15 ZA ZA2015/05093A patent/ZA201505093B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR094084A1 (en) | 2015-07-08 |
| TN2015000236A1 (en) | 2016-10-03 |
| ZA201505093B (en) | 2016-04-28 |
| CN104869988A (en) | 2015-08-26 |
| PE20151587A1 (en) | 2015-12-05 |
| MX362762B (en) | 2019-02-06 |
| BR112015014161B1 (en) | 2021-02-17 |
| MX2015008138A (en) | 2016-04-25 |
| JO3117B1 (en) | 2017-09-20 |
| CA2895574C (en) | 2019-11-26 |
| CN104869988B (en) | 2017-07-28 |
| CA2895574A1 (en) | 2014-06-26 |
| WO2014096133A1 (en) | 2014-06-26 |
| BR112015014161A2 (en) | 2017-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP17073191A (en) | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | |
| CR20150078A (en) | 1,4-DISPOSED PIRIDAZINE ANALOGS AND METHODS FOR THE TREATMENT OF CONDITIONS RELATED TO THE DEFICIENCY OF SMN | |
| DOP2014000064A (en) | COMPOUNDS 1-ARILCARBONIL-4-OXI-PIPERIDINA USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | |
| GT201500051A (en) | GLUCOSILCERAMIDE SINTASA INHIBITORS | |
| CU20160188A7 (en) | INDAZOLE COMPOUNDS SUBSTITUTED AS IRAK4 INHIBITORS | |
| MX2015006039A (en) | DERIVATIVES OF PIRIMIDIN-2, 4-DIAMINE FOR CANCER TREATMENT. | |
| MX2015011273A (en) | Use of pyrazolopyrimidine derivatives for the treatment of pi3kî´ related disorders. | |
| UY33910A (en) | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders | |
| ECSP16073171A (en) | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | |
| GT201300215A (en) | GLUCOSILCERAMIDE SINTASA INHIBITORS | |
| DOP2017000013A (en) | PREPARATION PROCEDURE FOR REPLACED 5-FLUORO-1H-PIRAZOLOPIRIDINAS | |
| CR20130023A (en) | PIRAZOLO [1,5-A] PYRIMIDINS FOR ANTIVIRAL TREATMENT | |
| SV2015005066A (en) | BIARIL-AMIDA COMPOUNDS AS CINASA INHIBITORS | |
| GT201400131A (en) | DERIVATIVES OF DIHIDRO-BENZO-OXAZINA AND DIHIDRO-PIRIDO-OXAZINA | |
| CR20140468A (en) | DIACILGLICEROL ACILTRANSFERASA 2 INHIBITORS | |
| BR112013025415A2 (en) | Methods for Increasing the Effectiveness of Folr1 Cancer Therapy | |
| CO7180199A2 (en) | Imidazotriazincarbonitriles useful as kinase inhibitors | |
| CR20150425A (en) | AZABENCIMIDAZOL COMPOUNDS AS INHIBITORS OF THE ISOZIMAS PDE4, FOR THE TREATMENT OF THE CENTRAL NERVOUS SYSTEM AND OTHER DISORDERS | |
| BR112015000399A2 (en) | pyrazolyl pyrimidine derivatives | |
| MX2015012427A (en) | COMPOUNDS OF HETEROARILO ACID MORFOLINONA AS MDM2 INHIBITORS FOR CANCER TREATMENT. | |
| CU24335B1 (en) | PIRIDOPIRIMIDINAS REPLACED AS INHIBITORS OF THE MEK KINASE AND USEFUL FOR THE TREATMENT OF CANCER | |
| CR20200177A (en) | BIHETEROARILO COMPOUNDS (DIVISIONAL 2015-0589) | |
| ES2570976T3 (en) | Condensed bicyclic 2,4-diaminopyrimidine derivative as dual inhibitor of ALK and FAK | |
| CR20150211A (en) | DIMERICAL COMPOUNDS | |
| CR20140553A (en) | PIPERIDINE PHENOXIETIL COMPOUNDS |